MODULE 1: Incorporation of Immunotherapeutic Strategies into the Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) — Dr Wakelee

• Design, eligibility criteria and key efficacy and safety findings from the Phase III IMpower010 trial evaluating atezolizumab versus best supportive care after adjuvant chemotherapy for completely resected NSCLC
• Recent FDA approval of adjuvant atezolizumab for patients with Stage II to Stage IIIA NSCLC and PD-L1 expression ≥1%; optimal integration into practice
• Recently presented data from the Phase III PEARLS/KEYNOTE-091 study of pembrolizumab as adjuvant therapy for Stage IB to IIIA NSCLC
• Key findings from the Phase III CheckMate 816 trial evaluating nivolumab in combination with chemotherapy as neoadjuvant therapy for resectable NSCLC; recent FDA approval of neoadjuvant nivolumab and appropriate identification of candidates for this strategy
• Long-term efficacy and safety findings, including 5-year overall survival data, from the Phase III PACIFIC trial evaluating consolidation durvalumab after chemoradiation therapy for unresectable Stage III NSCLC; patient selection for and practical implementation of consolidation durvalumab
• Mechanisms of antitumor activity of oleclumab and monalizumab; efficacy and safety observed with durvalumab in combination with oleclumab or monalizumab in the randomized Phase II COAST study
• Other data sets and ongoing clinical trials with immune checkpoint inhibitors for nonmetastatic NSCLC

MODULE 2: Contemporary Treatment for Localized and Metastatic NSCLC with EGFR Mutations — Dr Yu

• Principal efficacy and safety findings, including rates of central nervous system (CNS) disease recurrence, from the Phase III ADAURA trial evaluating adjuvant osimertinib for localized NSCLC with an EGFR mutation
• Recent FDA approval of adjuvant osimertinib; patient selection and optimal incorporation into clinical care
• Optimal first-line treatment for patients with metastatic NSCLC and EGFR tumor mutations, including those with CNS metastases
• Mechanisms of resistance to osimertinib; published findings with and ongoing evaluation of EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib and lazertinib combined with other agents for patients who experience disease progression on first-line osimertinib
• Available data with and ongoing evaluation of the novel HER3-directed antibody-drug conjugate patritumab deruxtecan for metastatic EGFR TKI-resistant NSCLC
• Efficacy and safety findings supporting the recent FDA accelerated approvals of amivantamab and mobocertinib for patients with metastatic NSCLC and EGFR exon 20 insertion mutations

MODULE 3: Research Advances Shaping the Current and Future Treatment of Metastatic NSCLC with ALK Rearrangements, ROS1 Rearrangements or RET Fusions — Dr Gainor

• Key findings with novel ALK inhibitors (eg, alectinib, brigatinib, lorlatinib) as first-line therapy for patients with NSCLC with ALK rearrangements; clinical factors in the choice of up-front treatment
• Indications for repeat biomarker testing for patients with progressive NSCLC with ALK rearrangements; selection of therapy for patients who experience disease progression on first-line ALK inhibition
• Efficacy and safety results with entrectinib for NSCLC with ROS1 fusions; appropriate integration into clinical practice, including for patients with CNS involvement
• Published data with and ongoing trials of other “next-generation” ROS1 inhibitors (eg, repotrectinib, lorlatinib)
• Available safety and efficacy results with selpercatinib or pralsetinib for RET fusion-driven advanced NSCLC; current role in clinical practice
• Design, eligibility and key endpoints of Phase III studies comparing first-line selpercatinib or pralsetinib to chemotherapy with or without pembrolizumab for patients with treatment-naïve NSCLC with RET fusions

MODULE 4: Targeting Alterations in MET, HER2, KRAS and Other Oncogenes in NSCLC — Dr Weiss

• Key efficacy and safety findings with capmatinib or tepotinib for patients with NSCLC with MET exon 14 mutations
• Current role and practical implementation of capmatinib and tepotinib in clinical practice
• Principal efficacy and safety findings with sotorasib for patients with pretreated NSCLC with KRAS G12C mutations; recent FDA accelerated approval and optimal integration into practice
• Recently presented results from the Phase II DESTINY-Lung01 study evaluating trastuzumab deruxtecan (T-DXd) for patients with NSCLC with HER2 mutations
• FDA breakthrough therapy designation for T-DXd and potential nonresearch role for patients with NSCLC with HER2 mutations
• Early data with and ongoing investigations of other novel agents and strategies (eg, telisotuzumab vedotin, datopotamab deruxtecan, seribantumab) for patients with actionable genomic abnormalities

MODULE 5: Current and Future Management of Metastatic NSCLC without a Targetable Tumor Mutation — Dr Langer

• Clinical trial database supporting the FDA approvals of anti-PD-1/PD-L1 antibody monotherapy and combined chemoimmunotherapy for patients with newly diagnosed metastatic NSCLC
• Available results with the use of cemiplimab in combination with platinum-based chemotherapy as up-front therapy for NSCLC
• Long-term follow-up from Phase III trials (CheckMate 227, CheckMate 9LA) evaluating first-line nivolumab/ipilimumab with and without chemotherapy for metastatic NSCLC; optimal integration into practice
• Principal findings from the Phase III POSEIDON trial evaluating first-line durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy
• Biologic rationale for targeting TROP2 in lung cancer; mechanism of action of and available data with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan for patients with progressive metastatic NSCLC
• Other promising agents and strategies (eg, patritumab deruxtecan, plinabulin) for metastatic NSCLC without a targetable tumor mutation

MODULE 6: Current Treatment Paradigm for Small Cell Lung Cancer (SCLC) — Dr Paz-Ares

• Long-term efficacy and safety findings from the Phase III CASPIAN and IMpower133 studies of durvalumab and atezolizumab, respectively, in combination with chemotherapy as first-line treatment for extensive-stage SCLC; factors in selecting a regimen
• Major efficacy and safety findings from key studies (eg, the pivotal Phase II basket trial, ATLANTIS) of lurbinectedin for patients with SCLC who experienced disease progression after prior chemotherapy
• Current clinical role of lurbinectedin for progressive SCLC; ongoing efforts to combine lurbinectedin with other systemic therapies
• Efficacy and safety results from randomized studies evaluating trilaciclib as a means to preserve bone marrow function during chemotherapy in patients with extensive-stage SCLC; recent FDA approval and optimal incorporation of trilaciclib into routine practice
• Other novel agents and strategies under investigation for patients with extensive- or limited-stage SCLC